Universal access to care for multidrug-resistant tuberculosis: An analysis of surveillance data

The Lancet Infectious Diseases

Volumn 13, Issue 8, 2013, Pages 690-697

  Falzon, Dennis ^a   Jaramillo, Ernesto ^a   Wares, Fraser ^a   Zignol, Matteo ^a   Floyd, Katherine ^a   Raviglione, Mario C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AFGHANISTAN; ANGOLA; ARTICLE; AZERBAIJAN; BANGLADESH; BELARUS; BRAZIL; CHINA; DEMOCRATIC REPUBLIC CONGO; DISEASE SURVEILLANCE; ETHIOPIA; HEALTH CARE ACCESS; HUMAN; INDIA; INDONESIA; KAZAKHSTAN; KENYA; KYRGYZSTAN; LUNG TUBERCULOSIS; MOLDOVA; MOZAMBIQUE; MULTIDRUG RESISTANT TUBERCULOSIS; MYANMAR; NEPAL; NIGERIA; NORTH KOREA; PAKISTAN; PERU; PHILIPPINES; PRIORITY JOURNAL; RUSSIAN FEDERATION; SOUTH AFRICA; SOUTH KOREA; THAILAND; UKRAINE; UZBEKISTAN; VIET NAM;

AFRICA; ANTITUBERCULAR AGENTS; ASIA, SOUTHEASTERN; ASIA, WESTERN; BRAZIL; EUROPE, EASTERN; FAR EAST; GOALS; HEALTH SERVICES ACCESSIBILITY; HUMANS; PERU; POPULATION SURVEILLANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 84880702669     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70130-0     Document Type: Article

References (30)

1. Global tuberculosis report 2012 (WHO/HTM/TB/2012.6) 2012, WHO, World Health Organization, Geneva.
2. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011, 38:516-528.
3. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012, 90:111-119D.
4. Skrahina A, Hurevich H, Zalutskaya A, et al. Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 2013, 91:36-45.
5. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380:1406-1417.
6. Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007, 12:E070517.1.
7. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
8. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012, 54:579-581.
9. Murase Y, Maeda S, Yamada H, et al. Clonal expansion of multidrug-resistant and extensively drug-resistant tuberculosis, Japan. Emerg Infect Dis 2010, 16:948-954.
10. Raviglione MC, Smith IM XDR tuberculosis-implications for global public health. N Engl J Med 2007, 356:656-659.
11. Resolution WHA62.15. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Sixty-second World Health Assembly, Geneva, Switzerland; May 18-22, 2009. Resolutions and decisions; annexes 2009, World Health Organization, Geneva, (WHA62/2009/REC/1). apps.who.int/gb/ebwha/pdf_files/WHA62-REC1/WHA62_REC1-en.pdf (accessed April 11, 2012).
12. The Global Plan to Stop TB 2011-15: transforming the fight towards elimination of tuberculosis (WHO/HTM/STB/2010.2) 2010, WHO, World Health Organization, Geneva.
13. WHO Global Task Force outlines measures to combat XDR-TB worldwide WHO, (May 22, 2013). http://www.who.int/mediacentre/news/notes/2006/np29/en/.
14. Guidelines for treatment of tuberculosis 2009, WHO, World Health Organization, Geneva, (WHO/HTM/TB/2009.420). 4th edn.
15. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005, 9:640-645.
16. Guidelines for surveillance of drug resistance in tuberculosis (WHO/TB/2009.422) 2009, World Health Organization, Geneva. 4th edn.
17. Global tuberculosis control: WHO report 2010 (WHO/HTM/TB/2010.7) 2010, World Health Organization, Geneva.
18. R: a language and environment for statistical computing 2012, R Project, R Foundation for Statistical Computing, Vienna.
19. Shin SS, Yagui M, Ascencios L, et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis 2008, 14:701-708.
20. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. (WHO/HTM/TB/2011.3) 2011, WHO, World Health Organization, Geneva.
21. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010, 51:6-14.
22. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2012, published online Oct 25, 2012. 10.1183/09031936.00134712.
23. Nathanson E, Nunn P, Uplekar M, et al. MDR Tuberculosis-Critical steps for prevention and control. N Engl J Med 2010, 363:1050-1058.
24. Keshavjee S, Farmer PE Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 2012, 367:931-936.
25. Rouzier VA, Oxlade O, Verduga R, Gresely L, Menzies D Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador. Int J Tuberc Lung Dis 2010, 14:1316-1322.
26. Chang K, Lu W, Wang J, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Infect 2012, 64:580-588.
27. WHO policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis (MDR-TB) 2008, WHO, World Health Organization, Geneva, (May 22, 2013). http://www.who.int/entity/tb/laboratory/line_probe_assays/.
28. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012, 56:3271-3276.
29. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012, 366:2151-2160.
30. Fitzpatrick C, Floyd K A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012, 30:63-80.